Overview of the Demonstration Projects
JW Sander
DOI: https://doi.org/10.1046/j.1528-1157.43.s.6.14.x
IF: 6.74
2002-01-01
Epilepsia
Abstract:As has been expressed by our previous speakers, Drs. Leonardi, Baker, and Kale, there exists a large burden of epilepsy and a wide gulf in the availability of treatment for those who need it most. Whereas epilepsy affects ∼50 million people in the world, and treatment is generally successful, a large proportion of people remain untreated in developing countries. In India, for example, it is estimated that ∼5 million of the 10 million people with epilepsy do not receive any appropriate treatment. For estimated treatment gaps for various other developing countries, see Table 1 of the article by Reynolds in this issue (page 10). In addition to the treatment gap, a wide gap exists between the need for antiepileptic drugs (AEDs) and their availability. Only 20% of the potential market for AEDs is in developed countries, but these countries receive >80% of the total global supply of AEDs. This means that developing countries receive only 10–20% of AEDs, yet they have a greater need for them. Although almost every country's epilepsy services could be improved, the greatest need would appear to be in developing countries. It was, therefore, suggested that projects should be set up to demonstrate whether epilepsy services can be provided in contexts of minimum resources. It was envisaged that such projects would not only practically help to meet the immediate need of the countries in which they were established, but that they would also provide approaches that other countries could take up and adopt in their own local situations. As these projects should help to illustrate good practice in providing epilepsy care, they should also both support Ministries of Health and encourage them to assign priority to epilepsy services. To support the provision of national epilepsy services by Ministries of Health in terms of identifying needs and promoting education, training, treatment, services, research, and prevention, the following objectives have been set for each demonstration project: To reduce the treatment gap and the physical and social burden of people with epilepsy by intervention at a community level. To train and educate health professionals. To dispel stigma and promote a positive attitude to people with epilepsy in the community. To identify and assess the potential for prevention of epilepsy. To develop worldwide models for promotion of epilepsy control for integration into the health systems of participating countries. Countries are selected for demonstration projects on the basis of their willingness to participate, availability of a World Health Organization (WHO) Centre or WHO Country Representative, an International League Against Epilepsy (ILAE), and an International Bureau for Epilepsy (IBE) chapter. The reason for such criteria is threefold. First, there need to be representatives of the collaborative partners of the Global Campaign (WHO, IBE, and ILAE) in each country. Second, we need people and organisations already committed to providing epilepsy care and who are aware of many of the issues involved in this care. Third, and most important, we need people in each country who can implement the project, and it is essential that these are local people who know the situation far better than those in Geneva or Amsterdam or London and who can ensure that the project is applicable to the local context. We also need an adequate supply of AEDs to ensure that treatment can be provided over the project's lifetime and beyond. In an ideal world, each project would be able to offer every type of AED to treat every different epileptic syndrome, with the possibility of surgery also being available. This ideal is, however, currently impracticable, and so AEDs to treat generalised tonic–clonic seizures have been made a priority. If these projects are successful, a broadening of their scope and of the treatment offered may well take place so that the ideal is approached, but such plans are for the future. It is hoped that one or two countries in each of the six WHO regions will eventually have a demonstration project. In the African Region (AFRO), Senegal and Zimbabwe have been selected, and in the American Region (AMRO), Argentina. The protocols for projects in these countries are currently being revised, and it is anticipated that they will begin their implementation later this year. In the Western Pacific (WPRO), the People's Republic of China recently published its protocol, and its project has begun to be implemented. The Global Campaign Board are in discussions regarding potential countries in the other WHO Regions of Eastern Mediterranean (EMRO), Europe (EURO), and South East Asia (SEARO). The Global Campaign's Secretariat oversees the day-to-day running of the Campaign. This includes raising awareness and ensuring adequate funding. However, management duties for the demonstration projects have been delegated to a Scientific Project Leader. The Project Leader liaises with local ILAE and IBE chapters to foster local ownership and community participation. This liaison also involves the relevant WHO Offices and Ministries of Health. In China, for example, Global Campaign representatives met with Ministry of Health officials in 1999 and 2000 to plan what kind of project would be suitable and how best to go about this. The project's protocol was then developed in conjunction with the Ministry, the WHO Representative in Beijing, and the Beijing Neurological Institute. It was recently published by WHO (under the reference WHO/MSD/MBD/00.11) 1 and is now about to be implemented. During the design process, the Project Leader helped and evaluated the project's protocol. An important aspect of such evaluation is ensuring that each project has sustainability built into its design. The Project Leader also is responsible for monitoring the projects to see how they are performing, and for writing up this performance for scientific journals. Each project will be led locally by Principal Investigators. They are responsible for constructing the project's protocol and ensuring that its implementation keeps to its budget and time scales. They are the focal points of the Campaign's relation with the project and the people through whom information will flow. Crucial to their work is ensuring that the project meets its outcome measures. Regional Facilitators will support them in their project's implementation. A diagram outlining the organisational structure for the demonstration projects is given (Fig. 1). Organisational structure of demonstration projects. Each project will have three broad areas of activity: Case ascertainment. Correctly identifying people with epilepsy is crucial for establishing the extent of a country's treatment gap and for ensuring that appropriate treatment is offered to those who need it. In China, for example, ∼2.5 million people in five selected provinces will be part of such a study. It is estimated that ∼8,800 people will initially be identified as having convulsive epilepsy, with 50% of these people not receiving appropriate treatment. Over the next 5 years of the project, it is thought that a further 875 people with epilepsy will be identified. Therefore, over the course of the project, it is likely that >7,000 people with untreated epilepsy will be treated. An intervention to improve treatment. To provide appropriate treatment, activities that ensure the supply of AEDs and/or facilitate their use in treatment are necessary. In China, village doctors will use a diagnostic questionnaire with those people identified as possibly having epilepsy. Senior primary health care physicians will confirm their diagnoses. People who are confirmed to have epilepsy and who are not receiving regular treatment will then be considered for inclusion in the project. Those people included will receive the AED phenobarbitone (PB) in accordance with a checklist of technical norms. Patients will be educated about their condition, and possible side effects, to encourage compliance with their treatment. Education. Incorrect perceptions about epilepsy often lead to people with epilepsy being stigmatised. Epilepsy also is often neglected in medical training. Therefore, the communities' and health professionals' awareness about epilepsy must be increased. The project in China will ensure that all physicians and a number of village doctors receive basic epilepsy training. This will cover epidemiology, causes, diagnosis, and management of epilepsy. Activities aimed at decreasing stigma will be targeted at school teachers. Attitudes regarding causes of epilepsy and shame associated with the condition will be covered. Local advocacy and support groups for people with epilepsy and their families also will be encouraged to develop. This is a key issue in any development programme, but it is particularly pertinent when it comes to providing epilepsy services. There is a great temptation to see the demonstration projects purely in demonstrational terms, so that they become only an interesting medical study that is published in a medical journal and that finishes its work when the study period of the project's life is completed. However, those who have received treatment through the project must continue receiving their treatment, not just to conform to international standards of medical studies, but also because a withdrawal of any treatment can provoke extremely adverse reactions, even death. Therefore, from the very outset, those involved in the projects must be thinking about how best the project's activities can be sustained in the long term. Past experiences in both Kenya and Malawi 2-5 have shown that although epilepsy care can be successfully provided, it is much harder to ensure that this care continues after those initiating the care have moved on elsewhere. People involved in development programmes across the world consistently advocate that the community must be involved in a programme for it to have any possibility of being sustained in the long term. Therefore, local people must be brought on board the demonstration project in its planning, implementation, and monitoring process. A sense of ownership and empowerment must be engendered so that local people feel that the project is theirs. However, for the Global Campaign's projects, further dimensions regarding sustainability must be added. The partner organisations within the Global Campaign also must see that this is not a short-term programme. They must be ensuring that their member organisations are fully behind the programme so that expertise can be shared and funds can be consistently provided. The WHO, IBE, and ILAE each have a responsibility to ensure adequate long-term funding or else, even with all the local participation in the world, the projects' activities will inevitably cease for want of resources. These organisations must carry through the ideals of the Global Campaign into the long term. The demonstration projects will involve much hard work and coordination and deserve sustained attention and support. The demonstration projects are being established to meet the needs of people with epilepsy in developing countries 6. They also are intended to encourage the high priority of epilepsy care and, in time, to offer transferable approaches to the provision of this care. In China, for example, it is hoped that the project will encourage other provinces to adopt its own successful activities so that a national model can be achieved. The activities in China and elsewhere also will be regularly written up for journals to encourage other countries to take on board their findings. By the end of this year, it is envisaged that four projects will be up and running and that six more will be in the process of designing their project's protocols. It is hoped that each project will help to meet the needs of people with epilepsy and so bring epilepsy out of the shadows in the long term.